X4 Pharmaceuticals secures up to $150 million senior debt facility with K2 HealthVentures
Bitget2026/10/08 11:03X4 Pharmaceuticals entered a senior secured term loan facility of up to USD 150 million with K2 HealthVentures. USD 80 million funded at closing, used to repay all obligations under the prior loan, including USD 75 million principal. Facility includes up to USD 70 million additional borrowing, subject to K2 HealthVentures approval and other conditions. New facility extends financing runway with a longer interest-only period, 48-month maturity, supports potential mavorixafor launch preparations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080700PRIMZONEFULLFEED9841976) on October 08, 2026, and is solely responsible for the information contained therein.
- X4 Pharmaceuticals entered a senior secured term loan facility of up to USD 150 million with K2 HealthVentures.
- USD 80 million funded at closing, used to repay all obligations under the prior loan, including USD 75 million principal.
- Facility includes up to USD 70 million additional borrowing, subject to K2 HealthVentures approval and other conditions.
- New facility extends financing runway with a longer interest-only period, 48-month maturity, supports potential mavorixafor launch preparations.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
